Anti-tumor agents of the KRAS gene variant for colorectal cancer patients and therapeutic effect prediction method

摘要

The present invention includes the following steps (1) ~ (2), α in colorectal cancer patients, α, α- trifluoro-thymidine and 5-chloro-6- (1- (2-imino pyrrolidinyl) methyl) method of predicting the therapeutic effect of chemotherapy with anti-tumor agent comprising 0.5: uracil hydrochloride salt molar ratio of 1: (1) detecting the presence or absence of a mutation in the KRAS gene contained in the biological sample taken from the patient, and (2) the result of the check in the step (1), if the KRAS gene is mutated, the patient the step of the chemotherapy may be predicted to be likely to exhibit a sufficient therapeutic effect on, I provide.